Mirviss Jeffrey B.

Mirviss Jeffrey B., EVP & President of Peripheral Interventions at Boston Scientific (BSX), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recent purchases recorded in SEC filings. Over 42 reported transactions, his total sales amount to $14.1 million, dwarfing his $1.07 million in buys. The bulk of his recent activity occurred in February 2025, with eight sales totaling over $2.8 million, including a $487,369 transaction on February 24 and a $279,552 sale the following day. Earlier that month, on February 12, he executed a larger disposition worth $1.37 million. Prior to this, his most significant sale in 2024 was a $4.79 million transaction on May 29, followed by a $963,930 sale on March 18. Mirviss’s transactions are exclusively tied to BSX, with no activity in other companies. The sales appear methodical, often clustered around specific dates, such as the February 2025 series, which included multiple dispositions ranging from $91,808 to $487,369. While some filings show $0 value transactions—likely representing option exercises or other non-monetary events—the overwhelming trend is one of divestment. This pattern suggests a long-term reduction in his equity position, though the reasons remain undisclosed in regulatory filings. The absence of any buys since at least early 2024 reinforces a clear directional bias toward liquidation rather than accumulation.